Showing 3881-3890 of 5956 results for "".
- BVI Medical Launches Educational Platform for Ophthalmology Professionalshttps://modernod.com/news/bvi-medical-launches-educational-platform-for-ophthalmology-professionals/2482639/BVI Medical announced the launch of EyeXchange Solutions, a platform designed to enhance vision care through comprehensive educational resources and clinical support. This initiative aims to empower surgical decision-making, enhance provider experiences, alleviate economic
- Harrow Partners with Cencora to Launch “Harrow Cares” Programhttps://modernod.com/news/harrow-partners-with-cencora-to-launch-harrow-cares-program/2482637/Harrow announced the launch of its “Harrow Cares” program through a strategic partnership with Cencora. Harrow Cares is designed to deliver a suite of access and affordability services, enhancing support for retina specialists, their staff, and patients.
- SeaBeLife Reports Promising In Vivo Results for Ophthalmic Gel Candidate for GAhttps://modernod.com/news/seabelife-reports-promising-in-vivo-results-for-it-ophthalmic-gel-candidate-for-ga/2482635/SeaBeLife announced in vivo results for its SBL03 drug candidate, an ophthalmic gel designed to combat necrotic retinal cell death in geographic atrophy (GA). The primary objective of the preclinical study was to assess
- Norlase Receives FDA 510(k) Clearance and CE Mark for LYNX Pattern Scanning Laser Indirect Ophthalmoscopehttps://modernod.com/news/norlase-receives-fda-510k-clearance-and-ce-mark-for-lynx-pattern-scanning-laser-indirect-ophthalmoscope/2482634/Norlase announced the FDA 510(k) clearance and CE Mark for Norlase LYNX, which the company describes as the world’s first and only pattern scanning laser indirect ophthalmoscope. Commercially available now, the LYNX is battery-powered and provides surgeons the abili
- RayOne EMV Toric IOL Approved by Health Canadahttps://modernod.com/news/rayone-emv-toric-iol-approved-by-health-canada/2482626/Rayner announced the approval of RayOne EMV Toric IOL by Health Canada. Developed in collaboration with Professor Graham Barrett, RayOne EMV and RayOne EMV Toric are the only patented aspheric IOLs that induce controlled positive spherical aberration to extend depth of focus, according
- Inflammasome Therapeutics Announces Positive Topline Data from K8 Implant Trial for GAhttps://modernod.com/news/inflammasome-therapeutics-announces-positive-topline-data-from-k8-implant-trial-for-geographic-atrophy/2482621/Inflammasome Therapeutics reported 3-month results from a clinical trial of its K8 implant in patients with geographic atrophy (GA). The study, conducted at the University of Kentucky (NCT06164587), demonstrated significant efficacy and safety following a single inject
- Visible Genomics Wins 2025 AMD Genetic Testing Company of the Year Awardhttps://modernod.com/news/visible-genomics-wins-2025-amd-genetic-testing-company-of-the-year-award/2482619/Visible Genomics, a provider of genetic testing solutions for severe ocular diseases, was named 'Life Sciences Review AMD Genetic Testing Company of the Year 2025.' This award recognizes the company’s innovative contributions to proactive care for advanced age-related macular degene
- AbbVie and Regenxbio Announce Updates on the ABBV-RGX-314 Clinical Program in DR and Wet AMDhttps://modernod.com/news/abbvie-and-regenxbio-announce-updates-on-the-abbv-rgx-314-clinical-program-in-dr-and-wet-amd/2482618/AbbVie and Regenxbio announced updates to the ABBV-RGX-314 gene therapy clinical program. Data from the ATMOSPHERE and ASCENT pivotal trials evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet AMD are expected in 2026. The co
- Sling Therapeutics Announces Positive Topline Results from Phase 2b/3 LIDS Trial of Linsitinib in Patients with TEDhttps://modernod.com/news/sling-therapeutics-announces-positive-topline-results-from-phase-2b3-lids-trial-of-oral-small-molecule-linsitinib-in-patients-with-ted/2482614/Sling Therapeutics announced topline efficacy and safety data from the phase 2b/3 LIDS trial of linsitinib in patients with active, moderate to severe Thyroid Eye Disease (TED). Linsitinib, Sling’s lead product candidate, is an oral small molecule, taken twice-daily
- Tangible Science Announces CEO Transitionhttps://modernod.com/news/tangible-science-announces-ceo-transition/2482613/Tangible Science, a provider of specialty contact lens technology, announced that Karen Havenstrite, PhD, MBA, co-founder and former Chief Technology Officer, has been appointed Chief Executive Officer. Dr. Havenstrite suceeds Victor McCray, MD, who will transition to the